Risk of transmission of amyloid β pathology via transfused blood products

The idea that a neurodegenerative disease could be transmitted via blood products is the kind of nightmare that keeps epidemiologists up at night. We've seen prions do it with vCJD, and now amyloid β is knocking on the same door. This isn't just a clinical footnote — it's a call to arms for open data and transparent research. If the risk is real, we need large-scale, openly shared donor and recipient cohorts to track this. Proprietary silos won't cut it when lives and blood supplies are on the line. The broader theme here is the tension between precaution and pragmatism. Blood banks already reject donors for a laundry list of reasons, but adding a potential Alzheimer's risk factor would be a massive shift. We're talking about millions of deferred donors and a possible blood shortage. The community needs to weigh in — and fast. This is exactly the kind of issue where open source principles — shared data, peer review, and public discourse — can prevent both panic and complacency. Also, let's not forget the ethical dimension. If transfusion can transmit amyloid β, then recipients have a right to know. That means informed consent protocols, longitudinal follow-ups, and a regulatory framework that's nimble enough to adapt. The Lancet paper is a spark, but the fire needs to be fueled by collaborative, open science. Otherwise, we're just guessing in the dark with a very precious resource.